Long-Term Results of a Phase 2 Clinical Trial of Radiation Volume and Dose Deintensification Following Transoral Robotic Surgery and Neck Dissection for Human Papillomavirus–Associated Oropharyngeal Squamous Cell Carcinoma
International Journal of Radiation Oncology*Biology*Physics · 2026-04-01
Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)
Lung Cancer · 2026-01-20 · 2 citations
Cardiac substructure radiotherapy dose and changes in physical activity and quality of life after chemoradiotherapy for NSCLC: a secondary analysis of the CLARITY prospective study
Clinical and Translational Radiation Oncology · 2025-11-14
Real World Radiographic Response Rates and Preoperative Attrition in Patients With Non–Small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy
American Journal of Clinical Oncology · 2025-11-07 · 1 citations
Outcomes of <scp>HPV</scp> + Oropharyngeal Carcinoma of Unknown Primary Following Transoral Robotic Surgery
The Laryngoscope · 2025-08-13 · 2 citations
Data from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaPreprint
2025-07-01
Survival after osimertinib dose-reduction, discontinuation in 1L <i>EGFR</i> -mutated metastatic non-small cell lung cancer (mNSCLC).
Journal of Clinical Oncology · 2025-05-28
EMBER-Lung: Electronic medical record boosting molecular testing in early stage NSCLC.
Journal of Clinical Oncology · 2025-05-28
Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC
JTO Clinical and Research Reports · 2025-05-26 · 2 citations
Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors
Investigational New Drugs · 2025-05-01 · 3 citations
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Clinical Cancer Research · 2025-04-29 · 20 citations
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis
Lung Cancer · 2025-04-19 · 5 citations
Tumor-intrinsic and immune-related features associated with treatment failure in human papillomavirus-related oropharyngeal cancer
JNCI Journal of the National Cancer Institute · 2025-03-11 · 2 citations
A Text Message Intervention to Minimize the Time Burden of Cancer Care
NEJM Catalyst · 2025-02-19 · 1 citations
Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis
JCO Oncology Practice · 2025-02-12 · 6 citations
“Off-Label” Use of Checkpoint Inhibitors in Patients With Negative or Unknown PD-L1 Status in Advanced Head and Neck Cancer
Journal of the National Comprehensive Cancer Network · 2025-02-11 · 2 citations
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies
Nature Medicine · 2025-01-20 · 71 citations
Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy
Clinical Lung Cancer · 2024-12-13 · 3 citations
Abstract 4137636: Cardiac radiation dose and changes in physical activity and quality of life in patients with locally advanced lung cancer
Circulation · 2024-11-12
Outcomes Following Treatment for Progression in Patients Treated With Durvalumab Consolidation in LA-NSCLC
Clinical Lung Cancer · 2024-11-10 · 3 citations